Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

5 Top Biotech Stocks That Look Vulnerable in 2018

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:BioPharma

Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.…

Continue Reading5 Top Biotech Stocks That Look Vulnerable in 2018

FDA Calls Bay Area Global Blood Therapeutics' Sickle Cell Drug a Breakthrough

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:BioPharma

The BTD decision for voxelotor was based on clinical data submitted from a trio of studies. Source: BioSpace

Continue ReadingFDA Calls Bay Area Global Blood Therapeutics' Sickle Cell Drug a Breakthrough

REGENXBIO Banks on Strong Gene Therapy Pipeline and Potential Partnerships

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:BioPharma

Gene therapy treatment is a high risk, high reward venture, but the promises of a therapy developed through these programs could be life-changing for patients. Source: BioSpace

Continue ReadingREGENXBIO Banks on Strong Gene Therapy Pipeline and Potential Partnerships

Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:BioPharma

Cellectar Biosciences is closing its manufacturing operations and contracting them out. Source: BioSpace

Continue ReadingJobs Lost as Cellectar Biosciences Shutters Manufacturing Operations

Bridging Clinical Research & Clinical Health Care: How to Improve Patient Centricity

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:BioPharma

For multiple perspectives on addressing this challenge, three respected individuals involved with the effort to bridge clinical research and clinical health care share their views. Source: BioSpace

Continue ReadingBridging Clinical Research & Clinical Health Care: How to Improve Patient Centricity

SoCal's Evolus Files for $75M IPO

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:BioPharma

Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering. Source: BioSpace

Continue ReadingSoCal's Evolus Files for $75M IPO

Mexican Drugmaker Warned for Adulterated Product

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:Drug Industry Daily

The FDA issued a warning letter to Prosana Distribuciones in Mexico City for serious GMP violations and for producing an adulterated drug product. Source: Drug Industry Daily

Continue ReadingMexican Drugmaker Warned for Adulterated Product

FDA and CTTI Launch Patient Forum to Boost Engagement in Drug Development

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:Drug Industry Daily

The Patient Engagement Collaborative is gearing up for a launch in early 2018. The new, external panel is being built by the FDA and the Clinical Trials Transformation Initiative (CTTI),…

Continue ReadingFDA and CTTI Launch Patient Forum to Boost Engagement in Drug Development

FDA Won’t Raise the Bar for Drugs Referencing Novo Nordisk

  • Post author:Sam
  • Post published:January 8, 2018
  • Post category:Drug Industry Daily

The FDA turned down a request from Novo Nordisk to deny ANDAs referencing its liraglutide-containing drugs without comparative studies. Source: Drug Industry Daily

Continue ReadingFDA Won’t Raise the Bar for Drugs Referencing Novo Nordisk

Rejected Again: Ablynx Turns Down Novo Nordisk's Sweetened $3.1B Bid

  • Post author:Sam
  • Post published:January 7, 2018
  • Post category:BioPharma

The offers underline Novo Nordisk's interest in expanding beyond diabetes and into the rare diseases market. Source: BioSpace

Continue ReadingRejected Again: Ablynx Turns Down Novo Nordisk's Sweetened $3.1B Bid
  • Go to the previous page
  • 1
  • …
  • 205
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.